Developer docs
API playgroundTry for free, no card

Search company profiles

Gen-Plus

Full company profile

uuid000io29

Namestring
Gen-Plus
Legal namestring
Gen-Plus GmbH & Co. KG
Websiteurl
gen-plus.de
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Gen-Plus GmbH & Co. KG is a Munich-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 1999, specializing in formulation development and GMP-certified manufacturing of complex and hard-to-formulate drug products. The company operates a 1000 sqm GMP facility and serves pharmaceutical clients across solid dosage forms (tablets, capsules, granules, pellets, lyophilisates), semi-solid formulations, transdermal patches, oral thin films, and micro/nanoemulsions. Its technology platform spans 30+ pharmaceutical technologies including hot melt extrusion for bioavailability enhancement, 2D/3D drug printing for personalized medicine, high containment capabilities for highly potent and cytotoxic APIs (OEB classes 4/5), multiple amorphization methods, and PLEASE laser perforation technology for transdermal peptide delivery.

The company generates revenue through project-based contract R&D services, feasibility studies, proof-of-concept work, GMP manufacturing of Phase I clinical trial samples (with IMP manufacturing capabilities for oral solids and extension to ODFs/TDS), patent support and freedom-to-operate consulting, and analytical services including in-vitro permeation testing. Its customer base is horizontally diversified across big pharma, generic manufacturers, biotech startups, OTC/dietary supplement companies, and compounding pharmacies, with project footprints in Europe, the USA, Australia, Israel, and Latin America. Gen-Plus is a privately held company that has operated as a subsidiary of Conscio Group since August 2022, following an earlier 2015 management buy-out from Teva/Ratiopharm by Dr. Markus Dachtler. Leadership transitioned in October 2023, with Tanja Führmann appointed CEO and Managing Director.

Short descriptiontext

Gen-Plus is a Munich-based pharmaceutical CDMO providing formulation development and GMP manufacturing of complex drug products (solids, semi-solids, transdermal patches, oral films) for big pharma, generics, biotech, and compounding pharmacy clients across Europe, the Americas, Australia, and Israel.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMünchen, Germany
HQ citystring
München
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical formulation development, GMP contract manufacturing, clinical trial sample manufacturing, drug delivery technologies, personalized medicine printing
Industry4 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract R&D Services
TypeProfessional Services
Description

Gen-Plus provides formulation development, feasibility studies, and proof-of-concept services for pharmaceutical companies. Revenue generated through project-based contract work from early idea phase through clinical trial sample production.

gen-plus.de
2GMP Manufacturing
TypeProfessional Services
Description

Certified manufacturer for Phase I clinical trial samples and IMP production. Revenue from GMP-compliant manufacturing of oral solids, with extension to oral films (ODFs) and transdermal therapeutic systems (TDS) under preparation.

gen-plus.de
3Patent and Consulting Services
TypeProfessional Services
Description

Patent support including freedom-to-operate strategies and general pharmaceutical consulting services.

gen-plus.de
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Project-based contract services
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing determined through direct consultation based on project scope, technology requirements, and development phase. No standard pricing tiers publicly available.

gen-plus.de
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Gen-Plus is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing formulation development and GMP manufacturing services for solid, semi-solid, transdermal, and personalized dosage forms. The company offers end-to-end services from early-stage feasibility studies through Phase I clinical trial sample production, specializing in complex and hard-to-formulate APIs, high-potency substances, narcotics, and 2D/3D printed personalized medicines across its 1,000 sqm GMP facility in Munich.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Successfully developed over 60 drug products using high-potent APIs
+1 more record
Product overview1 text field

Gen-Plus is a versatile Contract Development and Manufacturing Organization (CDMO) offering pharmaceutical innovation services from idea to production. The company operates as part of the Conscio Group and provides a comprehensive portfolio organized into three main categories: (1) Development Services including Original Products/NCE/NDA formulation, Generika/OTC, Biotech/Analytic, Feasibility Studies, Patent Support, Analytic Services, Narcotics Handling, and Consulting/Compliance; (2) Manufacturing Services for Investigational Medicinal Products (IMP) for clinical trials; and (3) Technology Platforms including 2D/3D Printing for personalized medication, Solid Dosage Forms, Semi-solid Dosage Forms, Patches/Oral Thin Films, Hot Melt Extrusion (HME), Micro-/Nanoemulsions, API Amorphization, High Containment Technologies, and PLEASE Laser Technology. The 1,000 sqm GMP facility enables the company to serve pharmaceutical clients from early development through clinical sample production and scale-up.

Product and service10 records
1Original Products / NCE / NDA Formulation Development
CategoryPharmaceutical R&D Services
2Generics / OTC Product Development
CategoryPharmaceutical R&D Services
3Biotech Formulation Development
CategoryPharmaceutical R&D Services
4Feasibility Studies and Proof of Concept
CategoryPharmaceutical R&D Services
5Investigational Medicinal Product (IMP) Manufacturing
CategoryPharmaceutical Manufacturing Services
6Patent Support Services
CategoryPharmaceutical Consulting
7Analytic Services
CategoryPharmaceutical Analytical Services
8Narcotics Handling Services
CategoryPharmaceutical Manufacturing Services
9Pharmaceutical Consulting and Compliance
CategoryPharmaceutical Consulting
102D/3D Drug Printing Technology Service
CategoryPharmaceutical Technology Platform
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-11
Description

Gen-Plus entered into a strategic partnership with Conscio Group, an independent international network of scientific service providers. The partnership enables an end-to-end service offering from idea to commercialization, combining Gen-Plus formulation and GMP production with Conscio's clinical trials, bioanalytical testing, and pharmaceutical testing capabilities.

2PCCA (Professional Compounding Centers of America)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-term collaboration with Houston-based PCCA, a leading supplier of APIs, excipients and drug delivery technology to compounding pharmacies. Gen-Plus provides formulation development, technical assistance, and GMP mindset compliance for personalized medication formulations. The collaboration includes stability testing and physicochemical characterization of compounded formulations.

gen-plus.de
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration in the PolyPrint project developing new 3D printers and polymers for pharmaceutical printing. TH Köln focuses on developing multi-head 3D printer systems for combining several active ingredients.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner in PolyPrint consortium developing pharmaceutical 3D printing. HHU team works on filament production processes and printing of first tablets using new polymers.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in PolyPrint research project developing pharmaceutical 3D printing. Merck's Life Science business sector developed new polymers enabling improved properties for extrusion, compression and stabilization of drug substances.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German specialty pharmaceutical manufacturer and CDMO with capabilities in solid dosage forms, OTC, and niche formulations. Comparable in geography, dosage-form focus, and serving German and European pharma clients.

TypeBroad incumbent
Description

Global CDMO (part of Thermo Fisher) offering comprehensive drug substance and drug product services including oral solids, semi-solids, and complex formulations. Broad incumbent competitor to Gen-Plus' formulation/GMP services.

TypeDirect peer
Description

UK-based CDMO specializing in early-phase drug development and clinical trial manufacturing, with a strong focus on integrated formulation-to-clinic services. Directly comparable to Gen-Plus' early-phase, formulation-led CDMO positioning.

4Laxxon Medical
TypeEmerging player
Description

Emerging 3D pharmaceutical printing company developing oral dosage forms with tailored release profiles. Comparable to Gen-Plus' 2D/3D printing and personalized medicine focus, though at an earlier commercialization stage.

TypeBroad incumbent
Description

Global CDMO leader with deep capabilities in oral solid dose, softgel, and novel drug delivery. Overlaps with Gen-Plus' solid/semi-solid and transdermal expertise but operates at vastly greater scale and modality breadth.

6Recipharm
TypeDirect peer
Description

European CDMO with extensive solid dose, semi-solid, and complex formulation capabilities serving big pharma and generics. Highly comparable in customer mix (big pharma + generic manufacturers) and dosage-form focus, though at much larger scale.

TypeDirect peer
Description

US-based pharmaceutical company pioneering 3D-printed drugs (Spritam). Most direct comparable to Gen-Plus' 2D/3D printing competence center for personalized, small-batch, point-of-care manufacturing.

TypeDirect peer
Description

One of the largest CDMOs in Europe, headquartered in Germany, with broad solid and semi-solid dosage form development and manufacturing capabilities. Comparable to Gen-Plus in focus on oral solids and complex formulations, but at materially greater scale.

TypeBroad incumbent
Description

Global CDMO providing clinical and commercial supply, manufacturing, and packaging for oral solid dose and specialty formulations. Overlaps with Gen-Plus' clinical trial material manufacturing focus at much broader geographic and scale footprint.

TypeDirect peer
Description

US-based small-molecule CDMO focused on complex oral solids, pre-formulation, and GMP clinical manufacturing. Comparable in targeting early-phase, complex-formulation clients with project-based service model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gen-Plus

Pharmaceutical Contract Development and Manufacturing (CDMO)gen-plus.de

Gen-Plus is a Munich-based pharmaceutical CDMO providing formulation development and GMP manufacturing of complex drug products (solids, semi-solids, transdermal patches, oral films) for big pharma, generics, biotech, and compounding pharmacy clients across Europe, the Americas, Australia, and Israel.

What Gen-Plus does

Gen-Plus GmbH & Co. KG is a Munich-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 1999, specializing in formulation development and GMP-certified manufacturing of complex and hard-to-formulate drug products. The company operates a 1000 sqm GMP facility and serves pharmaceutical clients across solid dosage forms (tablets, capsules, granules, pellets, lyophilisates), semi-solid formulations, transdermal patches, oral thin films, and micro/nanoemulsions. Its technology platform spans 30+ pharmaceutical technologies including hot melt extrusion for bioavailability enhancement, 2D/3D drug printing for personalized medicine, high containment capabilities for highly potent and cytotoxic APIs (OEB classes 4/5), multiple amorphization methods, and PLEASE laser perforation technology for transdermal peptide delivery.

The company generates revenue through project-based contract R&D services, feasibility studies, proof-of-concept work, GMP manufacturing of Phase I clinical trial samples (with IMP manufacturing capabilities for oral solids and extension to ODFs/TDS), patent support and freedom-to-operate consulting, and analytical services including in-vitro permeation testing. Its customer base is horizontally diversified across big pharma, generic manufacturers, biotech startups, OTC/dietary supplement companies, and compounding pharmacies, with project footprints in Europe, the USA, Australia, Israel, and Latin America. Gen-Plus is a privately held company that has operated as a subsidiary of Conscio Group since August 2022, following an earlier 2015 management buy-out from Teva/Ratiopharm by Dr. Markus Dachtler. Leadership transitioned in October 2023, with Tanja Führmann appointed CEO and Managing Director.

Gen-Plus firmographics

Firmographics
Name
Gen-Plus
Legal name
Gen-Plus GmbH & Co. KG
Website
https://gen-plus.de
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
Gen-Plus is a Munich-based pharmaceutical CDMO providing formulation development and GMP manufacturing of complex drug products (solids, semi-solids, transdermal patches, oral films) for big pharma, generics, biotech, and compounding pharmacy clients across Europe, the Americas, Australia, and Israel.
Ownership category
akta.pro rank

Gen-Plus industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical formulation development
  • GMP contract manufacturing
  • Clinical trial sample manufacturing
  • Drug delivery technologies
  • Personalized medicine printing

Where Gen-Plus is headquartered

Location

Headquarters

HQ city
München
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Gen-Plus business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract R&D Services: Gen-Plus provides formulation development, feasibility studies, and proof-of-concept services for pharmaceutical companies. Revenue generated through project-based contract work from early idea phase through clinical trial sample production.
  2. GMP Manufacturing: Certified manufacturer for Phase I clinical trial samples and IMP production. Revenue from GMP-compliant manufacturing of oral solids, with extension to oral films (ODFs) and transdermal therapeutic systems (TDS) under preparation.
  3. Patent and Consulting Services: Patent support including freedom-to-operate strategies and general pharmaceutical consulting services.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based contract services

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Gen-Plus product offering

Product offering

Core offering

Gen-Plus is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing formulation development and GMP manufacturing services for solid, semi-solid, transdermal, and personalized dosage forms. The company offers end-to-end services from early-stage feasibility studies through Phase I clinical trial sample production, specializing in complex and hard-to-formulate APIs, high-potency substances, narcotics, and 2D/3D printed personalized medicines across its 1,000 sqm GMP facility in Munich.

Product overview

Gen-Plus is a versatile Contract Development and Manufacturing Organization (CDMO) offering pharmaceutical innovation services from idea to production. The company operates as part of the Conscio Group and provides a comprehensive portfolio organized into three main categories: (1) Development Services including Original Products/NCE/NDA formulation, Generika/OTC, Biotech/Analytic, Feasibility Studies, Patent Support, Analytic Services, Narcotics Handling, and Consulting/Compliance; (2) Manufacturing Services for Investigational Medicinal Products (IMP) for clinical trials; and (3) Technology Platforms including 2D/3D Printing for personalized medication, Solid Dosage Forms, Semi-solid Dosage Forms, Patches/Oral Thin Films, Hot Melt Extrusion (HME), Micro-/Nanoemulsions, API Amorphization, High Containment Technologies, and PLEASE Laser Technology. The 1,000 sqm GMP facility enables the company to serve pharmaceutical clients from early development through clinical sample production and scale-up.

Differentiator

Problem solved

Functional benefit

Products and services

  • Original Products / NCE / NDA Formulation Development
  • Generics / OTC Product Development
  • Biotech Formulation Development
  • Feasibility Studies and Proof of Concept
  • Investigational Medicinal Product (IMP) Manufacturing
  • Patent Support Services
  • Analytic Services
  • Narcotics Handling Services
  • Pharmaceutical Consulting and Compliance
  • 2D/3D Drug Printing Technology Service

Quantifiable outcome

  • Successfully developed over 60 drug products using high-potent APIs
  • +1 more outcomes

Companies that use Gen-Plus

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Gen-Plus technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Gen-Plus partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Conscio GroupcoreStrategic or Co-development Partner · 11 August 2022Gen-Plus entered into a strategic partnership with Conscio Group, an independent international network of scientific service providers. The partnership enables an end-to-end service offering from idea to commercialization, combining Gen-Plus formulation and GMP production with Conscio's clinical trials, bioanalytical testing, and pharmaceutical testing capabilities.
  • PCCA (Professional Compounding Centers of America)coreStrategic or Co-development PartnerLong-term collaboration with Houston-based PCCA, a leading supplier of APIs, excipients and drug delivery technology to compounding pharmacies. Gen-Plus provides formulation development, technical assistance, and GMP mindset compliance for personalized medication formulations. The collaboration includes stability testing and physicochemical characterization of compounded formulations.
  • TH Köln (Technical University of Cologne)minorStrategic or Co-development PartnerResearch collaboration in the PolyPrint project developing new 3D printers and polymers for pharmaceutical printing. TH Köln focuses on developing multi-head 3D printer systems for combining several active ingredients.
  • Heinrich Heine University Düsseldorf (HHU)minorStrategic or Co-development PartnerResearch partner in PolyPrint consortium developing pharmaceutical 3D printing. HHU team works on filament production processes and printing of first tablets using new polymers.
  • MerckminorStrategic or Co-development PartnerPartner in PolyPrint research project developing pharmaceutical 3D printing. Merck's Life Science business sector developed new polymers enabling improved properties for extrusion, compression and stabilization of drug substances.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Gen-Plus competitors and assessment

Company assessment

Direct peers

  • Hermes Arzneimittel: German specialty pharmaceutical manufacturer and CDMO with capabilities in solid dosage forms, OTC, and niche formulations. Comparable in geography, dosage-form focus, and serving German and European pharma clients.
  • Quotient Sciences: UK-based CDMO specializing in early-phase drug development and clinical trial manufacturing, with a strong focus on integrated formulation-to-clinic services. Directly comparable to Gen-Plus' early-phase, formulation-led CDMO positioning.
  • Recipharm: European CDMO with extensive solid dose, semi-solid, and complex formulation capabilities serving big pharma and generics. Highly comparable in customer mix (big pharma + generic manufacturers) and dosage-form focus, though at much larger scale.
  • Aprecia Pharmaceuticals: US-based pharmaceutical company pioneering 3D-printed drugs (Spritam). Most direct comparable to Gen-Plus' 2D/3D printing competence center for personalized, small-batch, point-of-care manufacturing.
  • Aenova Group: One of the largest CDMOs in Europe, headquartered in Germany, with broad solid and semi-solid dosage form development and manufacturing capabilities. Comparable to Gen-Plus in focus on oral solids and complex formulations, but at materially greater scale.
  • CoreRx: US-based small-molecule CDMO focused on complex oral solids, pre-formulation, and GMP clinical manufacturing. Comparable in targeting early-phase, complex-formulation clients with project-based service model.

Broad incumbents

  • Patheon (Thermo Fisher Scientific): Global CDMO (part of Thermo Fisher) offering comprehensive drug substance and drug product services including oral solids, semi-solids, and complex formulations. Broad incumbent competitor to Gen-Plus' formulation/GMP services.
  • Catalent: Global CDMO leader with deep capabilities in oral solid dose, softgel, and novel drug delivery. Overlaps with Gen-Plus' solid/semi-solid and transdermal expertise but operates at vastly greater scale and modality breadth.
  • PCI Pharma Services: Global CDMO providing clinical and commercial supply, manufacturing, and packaging for oral solid dose and specialty formulations. Overlaps with Gen-Plus' clinical trial material manufacturing focus at much broader geographic and scale footprint.

Emerging players

  • Laxxon Medical: Emerging 3D pharmaceutical printing company developing oral dosage forms with tailored release profiles. Comparable to Gen-Plus' 2D/3D printing and personalized medicine focus, though at an earlier commercialization stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Gen-Plus social profiles

Digital presence

Gen-Plus compliance and trust

Trust signal

Compliance5 records

Gen-Plus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gen-Plus leadership team

Management profile

Number of profiles

Profiles2 records

Gen-Plus funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gen-Plus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gen-Plus

What does Gen-Plus do?

Gen-Plus is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing formulation development and GMP manufacturing services for solid, semi-solid, transdermal, and personalized dosage forms. The company offers end-to-end services from early-stage feasibility studies through Phase I clinical trial sample production, specializing in complex and hard-to-formulate APIs, high-potency substances, narcotics, and 2D/3D printed personalized medicines across its 1,000 sqm GMP facility in Munich.

Is Gen-Plus a public or private company?

Gen-Plus is a private company. It is classified as corporate owned and is currently operating.

When was Gen-Plus founded?

Gen-Plus was founded in 1999. It employs 11 to 50 people.

Where is Gen-Plus based?

Gen-Plus is headquartered in München, Germany, in the Europe region.

How does Gen-Plus make money?

Three revenue lines are on record. Contract R&D Services are the primary driver. The others are GMP Manufacturing and patent and Consulting Services.

Who are Gen-Plus's main competitors?

Direct peers on record are Hermes Arzneimittel, Quotient Sciences, Recipharm, Aprecia Pharmaceuticals, Aenova Group and CoreRx. Broad incumbents are Patheon (Thermo Fisher Scientific), Catalent and PCI Pharma Services. Laxxon Medical is listed as an emerging player.

Does Gen-Plus have an API?

No public API is recorded for Gen-Plus.

What industry is Gen-Plus in?

Gen-Plus's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales